| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,188,470 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,464 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,188,470 |
|
|
| Total
Value |
$52,464 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-05-14 |
3,246,424 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
152 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-10 |
4 |
B |
$11.08 |
$7,091 |
D/D |
640 |
3,237,484 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-05 |
4 |
B |
$11.09 |
$15,526 |
D/D |
1,400 |
3,235,764 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-09 |
4 |
B |
$11.19 |
$9,288 |
D/D |
830 |
3,236,844 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-10-06 |
4 |
B |
$11.27 |
$2,818 |
D/D |
250 |
3,236,014 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-23 |
4 |
B |
$11.40 |
$2,280 |
D/D |
200 |
2,963,914 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-29 |
4 |
B |
$11.62 |
$42,994 |
D/D |
3,700 |
2,968,314 |
3.23 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2015-04-06 |
4 |
S |
$11.68 |
$18,595 |
D/D |
(1,592) |
777,209 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-28 |
4 |
B |
$11.82 |
$3,546 |
D/D |
300 |
2,964,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-03-21 |
4 |
B |
$12.08 |
$5,798 |
D/D |
480 |
3,228,099 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-03-23 |
4 |
B |
$12.13 |
$2,790 |
D/D |
230 |
3,228,329 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-24 |
4 |
B |
$12.18 |
$4,872 |
D/D |
400 |
2,964,314 |
3.15 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-01-03 |
4 |
S |
$12.57 |
$66,080 |
D/D |
(5,257) |
880,419 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-22 |
4 |
B |
$13.10 |
$1,310 |
D/D |
100 |
2,963,714 |
3.15 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2015-01-05 |
4 |
S |
$13.79 |
$76,865 |
D/D |
(5,574) |
778,801 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-12-23 |
4 |
S |
$13.98 |
$1,460,756 |
D/D |
(104,489) |
1,151,488 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-12-24 |
4 |
S |
$13.98 |
$1,160,340 |
D/D |
(83,000) |
1,068,488 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-12-26 |
4 |
S |
$13.98 |
$887,730 |
D/D |
(63,500) |
1,004,988 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-12-29 |
4 |
S |
$13.98 |
$1,230,072 |
D/D |
(87,988) |
917,000 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-12-30 |
4 |
S |
$14.11 |
$2,822,000 |
D/D |
(200,000) |
717,000 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2014-09-12 |
4 |
S |
$14.24 |
$712,000 |
D/D |
(50,000) |
826,815 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-19 |
4 |
B |
$14.33 |
$2,866 |
D/D |
200 |
3,231,559 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-15 |
4 |
B |
$14.34 |
$3,370 |
D/D |
235 |
3,232,429 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-11 |
4 |
B |
$14.66 |
$2,639 |
D/D |
180 |
3,232,194 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-08 |
4 |
B |
$14.83 |
$1,780 |
D/D |
120 |
3,232,014 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-21 |
4 |
B |
$14.85 |
$3,341 |
D/D |
225 |
3,231,894 |
3.15 |
- |
|
152 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
